AbbVie continues to demonstrate solid revenue and earnings growth driven by the strong performance of Skyrizi and Rinvoq, which compensate for declines in Humira sales. Recent regulatory approvals and expanded market opportunities support the company's long-term growth prospects. Although AbbVie's forward price-to-earnings ratio has risen to 18.89, it still trades at a discount compared to its sector peers, with a forward PEG ratio of 1.40 indicating undervaluation. The analyst maintains a buy rating based on AbbVie's robust fundamentals and growth drivers, despite risks related to its drug pipeline and policy environment.
Investing in three blue-chip dividend stocks—Altria, AbbVie, and Chevron—each paying dividends quarterly on different schedules, can create a monthly income stream throughout the year. Altria pays in January, April, July, and October with a high yiel...
With inflation expected to remain high, five Dividend Aristocrats—companies with 25+ years of rising dividends—are recommended for investors seeking stable income and growth. These firms, including AbbVie, Chevron, PepsiCo, Procter & Gamble, and Targ...
AbbVie has submitted an application to the European Medicines Agency (EMA) for approval of SKYRIZI (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. This follows positive results from ...
